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Abstract 
 
Background: DOTATATE based radionuclides have added new options in the 
diagnosis and treatment of meningiomas; however, a reliable predictor of tumor growth 
has still not been established.   
Methods: Analysis of 64 meningiomas imaged with 68Ga-DOTATATE positron emission 
tomography (PET). Tumor growth rates were calculated by volumetric analysis of 
sequential MRI scans. Maximum of standardized uptake values (SUVmax) were 
correlated with tumor growth and co-variates. 
Results: WHO grades I and II meningiomas showed a correlation of SUVmax and tumor 
growth rate (meningiomas limited to the intracranial compartment: r=0.757, p<0.001, and 
transosseous growing meningiomas: r=0.819, p=0.024). SUVmax was significantly 
higher and the slope of the linear regression significantly steeper in transosseous 
compared to intracranial meningiomas (both p<0.001). The association remained 
significant in multivariate analysis and the prediction of tumor growth rate was 
independent of WHO grade. Anaplastic meningiomas showed no significant correlation 
of SUVmax and tumor growth.  
Conclusion: 68Ga-DOTATATE PET is a reliable predictor of tumor growth in WHO 
grades I and II meningiomas and provides additional information to conventional cross-
sectional imaging modalities. Hence, 68Ga-DOTATATE PET can assist in selecting the 
time point for treatment initiation. Furthermore, meningiomas with fast tumor growth and 
transosseous expansion elicit the highest DOTATATE binding; therefore, they might be 
especially suited for DOTATATE- based therapy. 
 
Key words: DOTATATE-PET; DOTATOC-PET; Meningioma; SSTR2 
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Introduction 
Meningiomas, with an annual incidence of 2.3 per 100,000, are the most common 
primary central nervous system (CNS) tumors and comprise nearly 34% of all CNS 
tumors.1-3 According to the World Health Organization (WHO), approximately 94% of 
meningiomas are classified as benign (WHO grade I), 5-7 % as atypical (WHO grade II) 
and 1-3% as anaplastic (WHO grade III).4-7 WHO grade I tumors have a good prognosis 
with a recurrence rate of approximately 5% after 5 years following gross total resection. 
WHO grade II and III meningiomas, however, remain challenging to treat and show 5 
year overall recurrence rates of approximately 40% and 80%, respectively.1,2 Multiple 
simultaneous meningiomas are recognized, especially in the context of 
neurofibromatosis II, and usually display a uniform histology.8,9  
The cross-sectional imaging modalities computed tomography (CT) and magnetic 
resonance imaging (MRI) are commonly applied for the identification and assessment of 
meningiomas.10 In meningioma management, the assessment of tumor growth rate 
(TGR) is critical to select an appropriate time point for therapy initiation and type of 
treatment, with surgery as the mainstay of primary treatment. However, surgery is 
challenging in meningiomas located in the skull base region, due to frequent 
transosseous growth and the close relationship to cranial nerves and other delicate 
anatomical structures.11  
Positron emission tomography (PET) with specific radiotracers is an imaging 
modality that adds molecular information. As meningiomas generally express 
somatostatin receptor subtype 2 (SSTR2),12 octreotide based radiotracers with high 
affinity to these receptors are suitable tumor imaging tracers.13 Primarily, 68Gallium (Ga) 
labeled DOTATATE and DOTATOC tracers are used to determine the extent of SSTR2-
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positive meningiomas.14-18 Using 68Ga-DOTATOC, Afshar-Oromieh and colleagues 
showed that PET has superior sensitivity in meningioma detection. Rachinger et al. 
demonstrated better tumor to non-tumor discrimination of PET/CT over contrast-
enhanced MRI.17-19 Furthermore, 68Ga-DOTATOC PET/CT information may strongly 
complement MRI and CT for intensity-modulated radiation therapy (IMRT) planning in 
patients with complex meningiomas of the skull base region for intensity-modulated 
radiation therapy (IMRT) planning.20   
In recent years, initial studies described 90Y or 177Lu radio-labeled somatostatin 
analogs to treat SSTR2-positive meningiomas. Bartolomei and colleagues demonstrated 
disease stabilization in 66% of patients with meningiomas after peptide receptor 
radionuclide therapy (PRRT),21 which was confirmed in a recent study that reported a 
high percentage of patients with disease stabilization.22 Accordingly, binding of the 
therapeutic radionuclide correlates with the pretherapeutic standardized uptake value 
(SUV) in PET, and ultimately with the SSTR2 expression of meningiomas.18,23 However, 
these results are conflicting, since SSTR2 expression itself is supposed to lead to 
growth inhibition in neoplastic and non-neoplastic tissue.24,25 Alternatively, binding may 
only reflect a more benign tumor behavior rather than beneficial response to therapy.  
We aimed to study the SUV reflecting SSTR2 expression as measured by 68Ga-
DOTATATE PET and its correlation to tumor growth in subsequent MR scanning. We 
hypothesized that SSTR2 uptake in 68Ga-DOTATATE PET not only accurately 
delineates meningiomas as previously reported but also provides critical information on 
tumor behavior for further treatment planning. 
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Materials and Methods 
 
Patient population 
All patients who received a 68Ga-DOTATATE PET for meningioma imaging from 
01/2011 to 12/2014 (n=45) were included in this study. Twenty-two patients were 
excluded because of insufficient MRI follow-up data, cerebral radiation therapy within the 
last two years or incomplete histological work-up. In patients with multiple meningiomas, 
we assessed up to a maximum of five separate lesions and analyzed the tumors with 
highest volume, resulting in 64 meningiomas from 23 patients. The study was approved 
by the local ethics committee (KEK-ZH 2014-0605). 
 
PET and MR data acquisition 
PET imaging was performed on a full ring PET/CT system (Discovery VCT, GE 
Healthcare, Waukesha, WI, United States of America). For attenuation correction 
purposes, a low-dose CT scan of the head was initially performed (10 mA, 120 kV, pitch 
of 0.984:1, collimation of 64 ×0.625 mm). The PET scan was initiated directly after the 
injection of 150 MBq 68Ga-DOTATATE and emission data were acquired over 60 
minutes (axial FOV of 153 mm covering the entire brain with one bed position). Emission 
data were corrected for randoms, dead time, scatter and attenuation and iteratively 
reconstructed (3 iterations, 18 subsets) using the CT. 
We selected one brain MRI examination before 68Ga-DOTATATE PET and 
another afterwards, resulting in at least 4 months of temporal difference between both 
images (median 11, minimum 4, maximum 20 months). All MRI examinations included 
axial T1- and T2-weighted images, and axial, coronal and sagittal T1 weighted images 
after the injection of Gadolinium contrast media (T1Gd). 
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PET and MR image analysis 
A board-certified nuclear medicine physician analyzed the PET images using 
PMOD Version 3.4 (PMOD Technologies Ltd, Zurich, Switzerland) and measured the 
maximal SUV (SUVmax) value in all meningiomas. For the quantitative evaluation of the 
PET data, frames acquired between 40 and 60 minutes were averaged. In the PET data 
set, volumes of interest (VOIs) were adjusted in 3 planes so that the entire meningioma 
was included.  
A second independent reader, blinded to the SUV, determined TGR of 
meningiomas in each patient. Meningiomas ‘en plaque’ were not assessed, as they are 
prone to measurement inaccuracies. As all other intracranial meningiomas 
corresponded approximately to a rotational ellipsoid, volume was calculated by 
multiplying the product of the three diameters by 0,523 (according to the formula 
4/3*π*a*b*c, whereas a, b, c are the lengths of each radius). The volumes of all 
transosseous meningiomas were determined by three-dimensional volumetric 
measurements (contour outline on all axial slices) on T1Gd images. Finally, the monthly 
growth rate was calculated by dividing the percentage change in size by the numbers of 
months between the two examinations.  
 
Grading and histological assessment 
 Histological grading according to the WHO classification was performed in at 
least one of the meningiomas by a board-certified neuropathologist blinded to clinical 
and radiographic details.4 Median time interval between histology and PET imaging was 
5.9 months. Since the majority of simultaneously occurring multiple meningiomas show 
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a uniform histology,8,9 all meningiomas from a given patient, even those that were not 
surgically sampled, were assigned the same WHO grade. To assess for potential bias 
when analyzing multiple meningiomas per patients, an additional evaluation with only 
one biopsied meningioma per patient was performed. For this additional assessment, we 
selected the largest meningioma, when histology of multiple meningiomas was available. 
  
Concomitant therapy 
We assessed concomitant therapy during MR follow-up and 5 patients received 
focal therapy (all WHO grade I or II), including stereotactic radiation (protons or photons) 
and embolization (total of 6/57 meningiomas), one patient with WHO grade III 
meningioma received systemic therapy with interferon alpha 2a. As all treatments aimed 
at tumor volume reduction or growth inhibition, we pooled treatments in statistical 
analysis. 
 
Statistical analysis 
Statistical analyses were performed using SPSS (version 21, IBM Corporation, 
Armonk, NY, USA). We calculated Pearson’s r and linear regression analysis, with 
values of R2 below 0.4 were considered weak, between 0.4 and 0.6 moderate and 
above 0.6 strong. We calculated significance of differences in regression slopes using 
the Chow test. In multivariate linear regression, SUVmax, age, sex, WHO grade, time 
between histology and PET, duration of follow-up, initial volume and concomitant 
therapy during follow-up were set as independent variables, and TGR as the dependent 
variable. Differences in mean values were tested with the Student’s t-test. Significance 
was defined as  p<0.05.  
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Results 
Sixty-four meningiomas in 23 consecutive patients were analyzed (29 WHO grade 
I, 28 grade II and 7 grade III). TGR in relation to SUVmax of 68Ga-DOTATATE PET is 
summarized in figure 1. Meningiomas were separated into three different clusters: 
transosseous growth, intracranial meningiomas of WHO grade I and II, and 
meningiomas of WHO grade III which were analyzed separately. Examples of PET and 
MR imaging of meningiomas are shown in figure 2. 
Eighteen patients with 50 meningiomas of WHO grade I and II had tumor growth 
limited to the intracranial compartment. TGR of these meningiomas strongly correlated 
with SUVmax of 68Ga-DOTATATE PET (r=0.757, p<0.001) and SUVmax correlated 
weakly with initial tumor volume in intracranial meningiomas (r=0.316, p=0.025) (Fig.1). 
In the patient analysis of biopsied meningiomas, correlation did not change (r=0.907, 
p<0.001). Both TGR and SUVmax did not differ in meningiomas with concomitant 
therapy during follow-up (n=4) versus non-treated meningiomas (n=46) (TGR: 9.8 ± 6.4 
vs. 9.8 ± 8.1, p=0.998 and SUVmax: 10.5 ± 3.4 vs. 11.2 ± 7.4, p=0.728). Correlation 
coefficient of TGR and SUVmax was stable when calculated for medicated meningiomas 
only but like because of low patient numbers, not to a significant degree (r=0.770, 
p=0.23). In multivariate linear regression, SUVmax remained a strong predictor for TGR 
(β=0.863, p<0.001; only co-variate: initial tumor volume β=-0.335, p<0.001; R2=0.7). 
Patients with intracranial meningiomas are summarized in table 1.  
Seven meningiomas from 5 patients showed transosseous growth into the skull 
base or temporal squama (all WHO grade I; 3 patients had meningiomas with 
transosseous growth as well as tumors limited to the intracranial compartment) (table 2). 
SUVmax values of these meningiomas were remarkably higher with a mean SUVmax of 
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43.3g/ml (range 18 - 70.7g/ml) compared to a mean SUVmax of 11.2g/ml (range 2.6 – 
32.0g/ml) for meningiomas without transosseous growth (p<0.001). Additionally, the 
slope of the linear regression coefficient was steeper in meningiomas with transosseous 
growth compared to meningiomas restricted to the intracranial compartment (a=5.5 and 
a=0.70, respectively, p<0.001). Again, TGR of transosseous meningiomas correlated 
significantly with SUVmax of 68Ga-DOTATATE PET (r=0.819, p=0.024) (Fig.1). The 
correlation coefficient remained stable at a high level in per patient analysis of biopsied 
meningiomas; however, like because of low patient numbers, not to a significant degree 
(r=0.789, p=0.113). TGR and SUVmax were concordantly lower in transosseous 
meningiomas (n=2) with treatment during follow-up versus non medicated meningiomas 
(n=5) (TGR: 5.8 ± 4.4 vs. 7.6 ± 2.9, p=0.667 and SUVmax: 34.1 ± 2.7 vs. 45.5 ± 24.6, 
p=0.361). SUVmax did not correlate with initial tumor volume in these meningiomas 
(p=0.251) and it was the only predictor of TGR in multivariate linear regression analysis 
(β=0.818, p=0.024, R2=0.7).  
WHO grade III meningiomas showed no significant correlation between TGR and 
SUVmax (p=0.518) (Fig.1). The monthly growth was remarkably high with relatively low 
SUVmax values (table 3). 
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Discussion 
Our study provides convincing evidence that high expression of SSTR2 as 
measured by SUVmax in Ga68-DOTATATE PET predicts faster growth in WHO grade I 
and II meningiomas whereas WHO grade III meningiomas did not show an association 
of TGR with tracer binding. Meningiomas with transosseous growth elicited considerably 
higher Ga68-DOTATATE binding. 
These data are surprising, since SSTR2 expression itself is supposed to lead to 
growth inhibition in various neoplastic tissues.24,25 The (patho-) physiological relevance 
of SSTR2 overexpression in meningiomas is not well understood,26 and growth 
stimulation in the presence of somatostation and its analogue octreotide has been  
reported.27 The Inhibitory effect of somatostatin in meningiomas is further challenged by 
the disappointing results of current treatment trials using somatostatin analogues.28,29 
The predictive value of TGR with Ga68-DOTATATE PET may be especially 
informative in meningiomas adjacent to delicate structures such as cranial nerves or 
arteries. Spefically, TGR with Ga68-DOTATATE PET may help in planning the optimal 
time point for surgery and for follow-up imaging. This is especially valuable for newly 
diagnosed meningiomas in such critical locations. SUVmax remains an independent 
predictor of TGR estimation in multivariate analysis, including tumor size and WHO 
grade, providing additional information to these estimates. Further studies have to 
assess the potential changes in management by the treating physician or the advisory 
tumor board in order to establish corresponding recommendations. 
 Our results also support further development of PRRT in meningiomas. As noted, 
Rachinger and colleagues showed a strong congruence of SUVmax in Ga68-DOTATATE 
PET with SSTR2 expression in the histologic preparations.18 In addition, Ga68-
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DOTATATE PET SUVmax correlates with radionuclide uptake in PRRT in 
meningiomas.23 This information taken together with the physical properties of 177Lu or 
90Y with a very limited maximal tissue penetration of the emitted β particles of 2 mm 
(maximum energy (Emax) 0.5 MeV) and 12 mm (Emax 2.3 MeV), respectively, allows 
for radiation dose estimation and consequently high tumor radiation doses, while 
minimizing the total radiation dose to normal brain parenchyma. As faster growing 
meningiomas have higher SUVmax, they will potentially also have higher radiation 
doses in PRRT.  Accordingly, this treatment option might be particularly target-oriented. 
Furthermore, transosseous meningiomas elicited considerable high DOTATATE-binding; 
therefore, PRRT appears especially suited to complement surgery or external radiation 
therapy for skull base and spheno-orbito-maxillar meningiomas.  
Finally, PET generates functional and morphological information that enhances 
treatment planning and dose calculation for IMRT.20 Notably, PET morphometry 
facilitates more accurate delineation of skull base meningiomas when compared to 
contrast-enhanced MRI alone.18  
WHO grade III meningiomas showed no correlation between SUVmax and TGR. 
Furthermore, the monthly growth was remarkably high with relatively low SUVs. This 
observation implies advanced dedifferentiation of the meningioma cells and limits the 
accuracy of predicting the growth rate with Ga68-DOTATATE PET. The clinical role of 
the other PET tracers like the widely used F18-fluorodeoxyglucose (FDG) in patients 
with dedifferentiated meningioma is still not clear. Arita and colleagues did not find any 
correlation between 18 F-FDG uptake and WHO grading or tumor-doubling time.30 On 
the other hand, Lee et al. reported that FDG uptake was a significant prognostic factor 
regarding tumor recurrence.31 Regarding 18F-Fluoro-tyrosine and C11-Methionine, 
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markers of L-amino acid transport and protein synthesis, only small numbers of 
dedifferentiated meningioma were assessed in recently published studies,32,33 thus their 
value as biomarkers for tumor growth rate or prognosis has not yet been established.  
Importantly, WHO grade III meningiomas show morphological features on MRI which 
help to diagnose this entity and guide PET use.10 In meningiomas with an unclear tumor-
brain interface, irregular tumor margins, heterogeneous contrast enhancement and 
missing capsular enhancement the probability of high-grade histology was 98%.34 
However, the present study does not allow any conclusion on the effect of PRRT on 
grade III meningiomas, as dedifferentiated cells may react differently to this therapy.   
 
The study design was retrospective and therefore, a selection bias cannot be 
ruled out. Another potential limitation is the relatively high percentage of patients with 
multiple meningiomas; at least one lesion from these patients was histologically 
evaluated, but not all lesions were subjected to histological assessment. Previous 
studies revealed that multiple meningiomas usually display a uniform histology and 
anaplastic meningiomas (WHO grade III) were rare among these.9,35 Therefore, we 
analyzed meningiomas of WHO grade I and II together.  
 
SUV, reflecting the SSTR2-density measured by 68Ga-DOTATATE PET, is a 
reliable predictor of TGR in WHO grades I and II meningiomas. This finding underlines 
its clinical importance for surgical planning and radiation therapy, since meningiomas 
with high SUVmax are at risk for progression and require either local or systemic 
treatment. Our study suggests that patients with high SUVmax might benefit from PRRT 
treatment, not only regarding dosimetric considerations but also with respect to risk for 
N-O-D-15-00627R1   Prediction of meningioma growth rate 
13 
progression. This holds especially true for transosseous meningiomas eliciting very high 
SSTR2 density. However, further studies are indicated to evaluate the therapeutic effect 
of PRRT in different histologic types of meningiomas and according to their SSTR2 
expression.  
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Figure captions 
 
 
Figure 1: Correlation between tumor growth rate and SUVmax. Meningiomas 
separated into three different clusters (intracranial growth, transosseous growth and 
anaplastic meningiomas).  
 
 
Figure 2: Examples of intracranial, transosseous and anaplastic meningiomas.  
From left to right baseline MRI, follow-up MRI and 68Ga-DOTATATE PET. 
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Reviewer #1: The authors studied 68Ga-DOTATATE PET in meningioma, and 
demonstrated a reliable predictive value for tumor growth in WHO grades I and II, using 
volumetric MR progression. 
 
The paper is highly original and interesting, opening exciting perspectives for peptide 
receptor radionuclide therapy. 
 
 We thank Reviewer #1 for this appraisal of our study! 
 
 
Some points should be addressed to improve the manuscript: 
 
1/ tumoral progression was evaluated using MR with 4 to 20 months of temporal difference. 
The authors have to clarify if patients had treatments during this period, and if it is the case 
how they manage this information in the statistical model 
 
We included detailed statements of concomitant therapy during the MR follow up time 
in the method section and added statistical analysis in the result section.  
We did not find significant differences in SUVmax and tumor growth rate between 
treated and non-treated meningiomas. Correlation coefficient was stable in the group 
of intracranial meningiomas (r=0.770 vs r=0.757 in the whole group); however like 
because of low patient numbers (n=4), not to a significant degree. 
We also added concomitant therapy as independent variable to multivariate analysis, 
which did not change results. 
 
 
2/ no significant correlation was found between DOTATE uptake and tumor growth for 
anaplastic meningioma. The authors should strengthen the discussion with the contribution 
of other tracers at this dedifferentiated stage (especially FDG) 
 
We added a paragraph in the discussion summarizing recently published studies 
regarding FDG-PET and PET markers of L-amino acid transport and protein synthesis 
(18F-Fluoro-tyrosine and C11-Methionine), commonly used in brain imaging.  
 
 We thank Reviewer #1 for the encouraging comments. 
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Reviewer #2: This manuscript looks at DOTATATE imaging in determining tumor growth 
rate (TGR). 
 
Introduction is well-written. 
 
Materials and Methods appear valid. The authors correlate growth rate with DOTATATE 
uptake.  They separate intracranial meningioma from transosseous growth and WHO Grade 
III meningiomas. 
 
 We appreciate these comments. 
 
 
Results demonstrate correlation of uptake with growth rate in intracranial meningioma and 
especially transosseous growth.  Uptake does not correlate with WHO Grade III 
meningiomas. 
 
It is unclear to me that Table 1-3 contributes to the content of this manuscript as it is quite 
raw and dense. 
 
We included these tables with clinical data as well as our measurements to ensure 
transparence and comprehension of our findings. If you consider this information as 
unnecessary, we certainly agree to remove these tables. 
 
 
Discussion is brief.  They speculate this can be used to determine when treatment should be 
offered.   
 
Our statement in the discussion: The predictive value of TGR with Ga68-DOTATATE PET may be especially 
informative in meningiomas adjacent to delicate structures such as cranial nerves or arteries. Specifically, TGR 
with Ga68-DOTATATE PET may help in planning the optimal time point for surgery and for follow-up imaging. 
This is especially valuable for newly diagnosed meningiomas in such critical locations. 
 
It would be helpful if the authors can give some guidelines how to interpret these values as to 
when to initiate treatment.  
 
Further studies have to assess these potential changes in management by the 
treating physician or the advisory tumor board in order to establish corresponding 
recommendations. (We added this statement to the above-mentioned text in the 
discussion) 
 
 
They also speculate DOTATATE as radionucleide therapy, which is very interesting. 
 
 
Overall, the data is reasonably presented.  Figure 1 should include r values. 
 
 We added r values to Figure 1. 
 
 
There are some spelling errors, including "somatostatin" on page 8, second paragraph.  Also, 
meningioma is spelled wrong in key for Table 1. 
 
We corrected mentioned errors and went carefully through the manuscript to check 
for spelling and grammar. 
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The data is certainly very interesting. Its applicability might be limited however as this is not a 
ubiquitous radiotracer. 
 
We thank Reviewer #2 for the helpful comments. 
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Table 1: Intracranial meningiomas 
ID Age 
 
Sex WHO 
grade 
Lesion with 
histology 
Time 
between 
MRI scans 
[months] 
Initial 
volume 
 
[mm3] 
Growth 
rate 
 
[%] 
SUVmax 
 
 
[g/ml] 
1 42.0 male I x 16 5726 14.58 22 
       3107 15.51 26.1 
       460 8.92 8.6 
      431 22.88 32 
*2 29.6 female I/II  10 2561 1.87 6.3 
    I/II   2312 3.77 6.8 
   II x  1689 21.51 19.1 
    I/II   952 13.79 10 
    I/II   795 7.51 6 
**3 44.3 female I  11 759 10.47 10.9 
      544 13.67 15.1 
      483 11.09 11.7 
4 68.2 male I  11 4142 14.71 14.9 
       435 13.58 11.1 
     x  345 10.58 10.7 
     x  251 4.26 6 
5 49.7 female I  8 1841 12.76 16 
    x  1054 18.38 18.8 
       748 26.05 20.2 
      483 16.40 15.9 
      460 29.76 24 
6 45.2 female I x 5 8186 4.33 9.3 
7 42.5 female II x 6 483 4.91 4.8 
      408 18.81 14.3 
8 73.4 female II  12 259 6.05 3.3 
      157 6.92 4.6 
     x  146 6.20 5.6 
       94 6.50 4.5 
9 62.0 female II  13 314 8.09 9.7 
    x  167 4.53 6 
10 37.2 male II  20 1849 0.82 3 
      1657 28.81 17.4 
     x  598 1.24 3.2 
       366 0.81 2.6 
       362 1.16 3.5 
11 28.4 female II x 13 226 2.96 3.8 
     x  176 4.04 4.2 
       75 4.48 5 
12 7.0 male II x 10 925 2.12 4.7 
13 63.1 female II x 7 1255 7.08 7.5 
14 68.1 female II x 6 316 1.83 7.1 
      774 18.18 12.9 
15 52.2 female II  12 10632 3.38 22 
       1245 2.24 20.9 
     x  322 2.57 8 
16 75.1 male II  10 2457 10.72 14 
     x  1809 3.18 7.6 
17 64.5 female II x 11 63 0.16 2.9 
***18 68.7 male II  5 264 23.96 18.9 
       188 13.91 15.7 
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* Patient with ID #2 had meningiomas with WHO grade I and II in histology (intrancranial and 
transosseus); therefore, menigiomas without biopsy were not allocated to a specific WHO grade 
(as indicated by ‘I/II’) 
** Patient with ID #3 had intracranial and transosseous meningiomas, the latter was operated 
and histology was obtained 
*** Patient with ID #18 received total resection of another meningioma from which histology was 
obtained  
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Table 2: Transosseous meningiomas 
ID Age 
 
Sex WHO 
grade 
Lesion with 
histology 
Time 
between 
MRI scans 
[months] 
Initial 
volume 
 
[mm3] 
Growth 
rate 
 
[%] 
SUVmax 
 
 
[g/ml] 
*1 42.0 male I x 16 23995 10.32 69.3 
       1271 7.98 45.8 
       1391 4.31 23.8 
*2 29.6 female I x 10 941 10.42 70.7 
*3 44.3 female I x 11 1640 5.06 18 
19 46.5 female I x 5 565 8.93 35.7 
20 52.2 female I x 4 7362 2.67 32.5 
 
*these patients elicited intracranial and transosseous meningiomas 
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Table 3: Anaplastic meningiomas 
ID Age 
 
Sex WHO 
grade 
Lesion with 
histology 
Time 
between 
MRI scans 
[months] 
Initial 
volume 
 
[mm3] 
Growth 
rate 
 
[%] 
SUVmax 
 
 
[g/ml] 
21 39.0 female III x 7 31777 19.48 5 
22 78.2 female III x 7 2921 104.42 10.7 
23 61.8 female III  7 1486 126.02 11.2 
     x  205 173.29 9.4 
       377 392.60 12.8 
       78 177.53 6.6 
       59 385.33 6.6 
 


